PRESENTATION
Q2 2024 — Presentation
Q2 2024PDF · 13 pages194 KB
Elevance Health 2Q 2024 Earnings Presentation July 17, 2024 -- 1 of 13 -- 2 Key Highlights • Elevance Health second quarter results reflect disciplined execution of our strategic initiatives during a dynamic time for the industry • 2Q 2024 adjusted diluted EPS of $10.12 grew 12% year-over-year • 2Q 2024 adjusted operating gain of $2.8B grew 6% year-over-year 2Q 2024 Results 1 • Reaffirmed 2024 adjusted diluted EPS guidance of at least $37.20, reflecting growth of 12% year-over-year • Continue to optimize our Health Benefits segment through ongoing margin recovery from pandemic-era lows in our commercial risk-based health plans and disciplined execution in government businesses • Guidance embeds investment in strategic growth initiatives, notably in CarelonRx, as we integrate recent acquisitions and scale key value drivers 2024 Outlook 2 • Executing on our enterprise strategy, to accelerate capabilities and services in Carelon by expanding and scaling our enterprise flywheel for growth • Minimizing barriers to whole health for Medicaid members impacted by eligibility redeterminations • Building a sustainable Medicare Advantage business for the long-term • Adjusted earnings per share growth algorithm provides a clear path to sustainable growth through upper single digit growth in enterprise operating revenue, margin expansion from disciplined pricing and operational transformation, and balanced capital deployment Strategic Focus Areas 3 -- 2 of 13 -- 33 Key Highlights • Elevance Health second quarter results reflect focused execution of our enterprise strategy in a dynamic operating environment • Operating revenue of $43.2B includes the impact of membership attrition in Medicaid • Benefit expense ratio of 86.3% improved 10 basis points driven by premium yields, inclusive of disciplined commercial underwriting • Adjusted operating expense ratio of 11.5% includes investment in strategic growth initiatives, notably in CarelonRx • Adjusted operating gain grew 5.8% driven by improved performance on risk-based contracts in Carelon 2Q 2024 Results Change (%/bps/$) 2Q 2023 2Q 2024 Elevance Health (0.4%) $43.4B $43.2B Operating Revenue 1 (10) bps 86.4% 86.3% Medical Loss Ratio 50 bps 11.0% 11.5% Adjusted Operating Expense Ratio1,2 5.8% $2.7B $2.8B Adjusted Operating Gain1,2 40 bps 6.2% 6.6% Adjusted Operating Margin 1,2 22.1% $416M $508M Net Investment Income 11.9% $9.04 $10.12 Adjusted diluted EPS2 ($1.5B)3 $2.0B $0.4B Operating Cash Flow 1. See “Basis of Presentation” on slide 10 herein. 2. See “GAAP Reconciliation” on slides 11 and 12 herein. 3. Figures may not foot due to rounding. Enterprise Results -- 3 of 13 -- 44 Key Highlights • Health Benefits demonstrated the resilience of our diversified mix of business in the quarter • Operating revenue was impacted by declines in Medicaid membership, partially offset by premium rate increases to cover medical cost trends • Operating gain increased 0.3%, driven by disciplined underwriting, partially offset by membership attrition • Operating margin expanded 20 basis points due to the recovery of commercial margins from pandemic era lows • Membership of 45.8M reflects attrition in Medicaid, partially offset by strong growth in ACA health plan membership Change (%/bps) 2Q 2023 2Q 2024 Health Benefits (2.2%) $38.0B $37.2B Operating Revenue 1 0.3% $2.1B $2.1B Operating Gain1 20 bps 5.6% 5.8% Operating Margin 1 (4.6%) 48.0M 45.8M Membership 2 1. See “Basis of Presentation” on slide 10 herein. 2. Health Benefits Membership for the three months ended June 30, 2023, is restated to reflect a change in BlueCard® membership to align to the Blue Cross Blue Shield Association reporting methodology. For the three months ended June 30, 2023, BlueCard® membership has been restated lower by 17K. Health Benefits 2Q 2024 Results -- 4 of 13 -- 55 Key Highlights • Carelon delivered growth in services while scaling key value drivers • Serves as the enterprise flywheel for growth, integrating physical, behavioral, social and pharmacy services to deliver whole health, affordably • CarelonRx operating revenue of $8.8 billion driven by strong external member growth and the acquisition of Paragon Healthcare; operating gain of $497 million includes ongoing investments in pharmacy home delivery and specialty services • Carelon Services operating revenue of $4.5 billion grew 26%; operating gain of $208 million grew over 32% driven by improved performance on risk- based arrangements 2Q 2024 Results Change (%/bps) 2Q 2023 2Q 2024 Carelon 10.3% $12.1B $13.3B Operating Revenue 1 8.0% $653M $705M Operating Gain1 (10) bps 5.4% 5.3% Operating Margin 1 1.0% 77.4M 78.2M Adjusted Scripts (1.3%) 103.6M 102.3M Consumers Served 1. See “Basis of Presentation” on slide 10 herein. Health Services -- 5 of 13 -- 66 Flywheel Supports Our Long-Term Growth Algorithm Health Benefits Optimize the Core Invest in Growth Accelerate Targeting at least 12% average annual growth in Adjusted Diluted Earnings Per Share Approximately 46M medical members balanced across commercial, Medicaid and Medicare, leveraging the assets and capabilities of Carelon to accelerate growth Integrated portfolio of whole health solutions connecting care across physical, behavioral, social, and pharmacy needs to bend the cost curve, enhance consumer experiences, and deliver whole health, affordably Health Services -- 6 of 13 -- 77 Adjusted Operating Gain – Upper Single Digit to Low Double Digit CAGR 1 Long-Term Growth Algorithm Revenue Growth Upper Single Digit CAGR 1 Adjusted Operating Margin Expanding to 6.5% - 7.0% by 2027 Capital Deployment Approximately 4% Contribution to Adjusted Diluted EPS CAGR 1 Health Benefits Mid to Upper Single Digit CAGR Driven by membership growth, cost trend, geographic expansion, and growth in specialized populations Carelon Services Upper Teens to Low Twenties CAGR Driven by risk-based revenue growth including M&A CarelonRx Low-Double Digit CAGR Driven by script volumes and drug mix Transforming our business processes by leveraging new technologies across operations Commitment to operating efficiency and optimizing core businesses Effective medical management Underwriting discipline Share Repurchases Organic Reinvestment Programmatic M&A targeting integrated solutions that strengthen health plan competitiveness + + Targeting at least 12% average annual growth in Adjusted Diluted EPS 1. CAGR = Compound Annual Growth Rate Target. -- 7 of 13 -- 88 Committed to Strong Growth Over the Long-Term M&A/ Organic Reinvestment 50% Share Repurchase 30% Dividends 20% 5.3% 6.5% – 7.0% 2022 2027 Target $156B Upper Single Digit CAGR2,3 2022 2027 Target Elevance Health 5.8% Mid to Upper Single Digit 2022 2027 Target $41B Mid Teens CAGR2,3 2022 2027 Target Carelon 4 4.3% 5.5% – 6.5% 2022 2027 Target $138B Mid to Upper Single Digit CAGR2,3 2022 2027 Target Health Benefits Capital Allocation Targeting at least 12% average annual growth in Adjusted Diluted EPS Operating Margin 1 Revenue1 (in Billions) 1. 2022 Operating Revenue and Operating Margin for Health Benefits, Carelon, and Elevance Health have been updated to reflect restated financials. 2. CAGR = Compound Annual Growth Rate Target. 3. Five-Year CAGR target for 2022 – 2027. 4. The CAGR target for revenue from 2022 – 2027 and the operating margin target in 2027 for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin target for CarelonRx, and (ii) an upper teens to low twenties revenue CAGR and mid to upper single-digit operating margin for Carelon Services. -- 8 of 13 -- 9 Forward-Looking Statements This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations. -- 9 of 13 -- 10 Non-GAAP Measures and Basis of Presentation This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available on the last slide of this document. Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. -- 10 of 13 -- 11 11 Elevance Health GAAP Reconciliation — Shareholders’ Net Income and Shareholders’ Earnings Per Diluted Share Six Months Ended Jun 30 Three Months Ended Jun 30 Change 2023 2024 Change 2023 2024 (In millions, except per share data) 18.3% $3,842 $4,546 24.1% $1,853 $2,300 Shareholders' net income Add / (Subtract): 456 278 221 162 Amortization of other intangible assets 234 246 121 85 Net losses on financial instruments 81 116 55 64 Transaction and integration related costs1 3 11 2 9 Litigation and settlement expenses1 — — — 4 Business optimization charges 1 — (240) — (240) Gain on sale of business (200) (103) (103) (22) Tax impact of non-GAAP adjustments 574 308 296 62 Net adjustment items 9.9% $4,416 $4,854 9.9% $2,149 $2,362 Adjusted shareholders' net income 20.7% $16.10 $19.44 26.4% $7.79 $9.85 Shareholders’ earnings per diluted share Add / (Subtract): 1.91 1.19 0.93 0.69 Amortization of other intangible assets 0.98 1.05 0.51 0.36 Net losses on financial instruments 0.34 0.50 0.23 0.27 Transaction and integration related costs1 0.01 0.05 0.01 0.04 Litigation and settlement expenses1 — — — 0.02 Business optimization charges 1 — (1.03) — (1.03) Gain on sale of business (0.84) (0.44) (0.43) (0.09) Tax impact of non-GAAP adjustments 2.40 1.32 1.25 0.27 Net adjustment items 12.2% $18.50 $20.76 11.9% $9.04 $10.12 Adjusted shareholders’ earnings per diluted share Six Months Ended Jun 30 Three Months Ended Jun 30 Change 2023 2024 Change 2023 2024 (In millions) 17.1% $5,060 $5,925 22.3% $2,441 $2,986 Income before income tax expense (803) (973) (416) (508) Net investment income — (240) — (240) Gain on sale of business 234 246 121 85 Net losses on financial instruments 512 545 261 280 Interest expense 456 278 221 162 Amortization of other intangible assets 5.9% $5,459 $5,781 5.2% $2,628 $2,765 Reportable segments operating gain 1. Adjustment item resides in the Corporate & Other reportable segment. -- 11 of 13 -- 12 12 Elevance Health GAAP Reconciliation — Operating Gain, Operating Expense Ratio, and 2024 Outlook Six Months Ended Jun 30 Three Months Ended Jun 30 Change 2023 2024 Change 2023 2024 (In millions) 3.5% $9,618 $9,952 5.1% $4,818 $5,066 Operating expense Add / (Subtract): (81) (116) (55) (64) Transaction and integration related costs1 (3) (11) (2) (9) Litigation and settlement expenses1 — — — (4) Business optimization charges 1 (84) (127) (57) (77) Net adjustment items 3.1% $9,534 $9,825 4.8% $4,761 $4,989 Adjusted operating expense 0.3% $85,275 $85,496 (0.4%) $43,377 $43,223 Operating revenue 30 bp 11.3% 11.6% 60 bp 11.1% 11.7% Operating expense ratio 30 bp 11.2% 11.5% 50 bp 11.0% 11.5% Adjusted operating expense ratio Six Months Ended Jun 30 Three Months Ended Jun 30 Change 2023 2024 Change 2023 2024 (In millions) 5.9% $5,459 $5,781 5.2% $2,628 $2,765 Reportable segments operating gain Add / (Subtract): 81 116 55 64 Transaction and integration related costs1 3 11 2 9 Litigation and settlement expenses1 — — — 4 Business optimization charges 1 84 127 57 77 Net adjustment Items 6.6% $5,543 $5,908 5.8% $2,685 $2,842 Reportable segments adjusted operating gain Full Year 2024 Outlook At least $34.05 Shareholders’ earnings per diluted share Add / (Subtract): $2.18 Amortization of other intangibles $1.61 Net losses on financial instruments $1.21 Transaction and integration related costs1 $0.07 Litigation and settlement expenses1 ($1.03) Gain on sale of business Approximately ($0.89) Tax impact of non-GAAP adjustments $3.15 Net adjustment items At least $37.20 Adjusted shareholders’ earnings per diluted share 1. Adjustment item resides in the Corporate & Other reportable segment. -- 12 of 13 -- -- 13 of 13 --